/manager/Index ${session.getAttribute("locale")} 5 Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial /manager/Repository/uon:19871 Wed 11 Apr 2018 14:09:42 AEST ]]> Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer /manager/Repository/uon:14178 Wed 11 Apr 2018 11:03:59 AEST ]]> Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial /manager/Repository/uon:20763 Wed 11 Apr 2018 09:54:54 AEST ]]> Predictive algorithms for adjuvant therapy: transATAC /manager/Repository/uon:12497 Sat 24 Mar 2018 08:15:55 AEDT ]]> Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer /manager/Repository/uon:13280 Sat 24 Mar 2018 08:15:16 AEDT ]]> Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial /manager/Repository/uon:11280 35 kg/m2) at baseline had more recurrences than those women with a low BMI (BMI < 23 kg/m2; adjusted hazard ratio [HR], 1.39; 95% CI, 1.06 to 1.82; Pheterogeneity = .03) and significantly more distant recurrences (adjusted HR, 1.46; 95% CI, 1.07 to 1.61; Pheterogeneity = .01). Overall, the relative benefit of anastrozole versus tamoxifen was nonsignificantly better in thin women compared to overweight women. Conclusion: These results confirm the poorer prognosis of obese women with early-stage breast cancer. Recurrence rates were lower for anastrozole than tamoxifen for all BMI quintiles. Our results suggest that the relative efficacy of anastrozole compared to tamoxifen is greater in thin postmenopausal women and higher doses or more complete inhibitors might be more effective in overweight women, but this requires independent confirmation.]]> Sat 24 Mar 2018 08:12:44 AEDT ]]> Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC Study /manager/Repository/uon:11225 Sat 24 Mar 2018 08:11:14 AEDT ]]> Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen /manager/Repository/uon:11170 Sat 24 Mar 2018 08:10:42 AEDT ]]> Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial /manager/Repository/uon:11140 Sat 24 Mar 2018 08:10:29 AEDT ]]> Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study /manager/Repository/uon:18999 Sat 24 Mar 2018 08:05:34 AEDT ]]> Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data /manager/Repository/uon:19000 Sat 24 Mar 2018 08:05:34 AEDT ]]> Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the arimidex, tamoxifen alone or in combination trial /manager/Repository/uon:17517 Sat 24 Mar 2018 08:03:50 AEDT ]]> Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors /manager/Repository/uon:17755 Sat 24 Mar 2018 07:57:21 AEDT ]]> Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial /manager/Repository/uon:5453 Sat 24 Mar 2018 07:48:12 AEDT ]]> Estrogen receptor expression in 21-gene recurrence score predicts increased late recurrence for estrogen-positive/HER2-negative breast cancer /manager/Repository/uon:22830 interaction = 0.004). Estrogen receptor transcript levels showed inverse prediction across the time windows: HR, 0.88 (0.73–1.07) and 1.19 (0.99–1.43), respectively (Pinteraction = 0.03). Similar time-, module-, and estrogen-dependent relationships were seen for distant recurrence. Conclusions: Patients with tumors with high estrogen receptor transcript levels benefit most from 5 years' endocrine therapy but show increased recurrence rates after 5 years and may benefit from extended therapy. Improved prognostic profiles may be created by considering period of treatment and follow-up time.]]> Sat 24 Mar 2018 07:16:07 AEDT ]]>